Trial Profile
Imatinib discontinuation for Chronic Myelogenou Leukemia-Chronic Phase with 2 years complete molecular remission.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms DOMEST
- 09 Dec 2013 New trial record